- 3-2-1 Health Tech
- Posts
- 3-2-1 Cardiomyopathy
3-2-1 Cardiomyopathy
3 health tech startups, 2 actionable insights, and 1 key resource at the intersection of medicine and emerging tech.
Priyanka Vaidya
July 28, 2025 • Estimated Reading Time: 5 minutes
🌟 Weekly Note
Exciting update this week! I’ve launched a fresh new design template (shoutout to @beehiiv 👏) and introduced a ‘Chat with Me’ link.
Whether you’re building in Healthcare x AI, exploring Women’s Health, refining your Product or Business Strategy, navigating Fundraising, or just curious to connect: let’s talk!
🗓️ Let’s chat!
I’d love to hear more about your health tech journey and share insights from mine.
Cardiomyopathy is a disease in which the heart muscle becomes abnormal, either enlarged, thickened, or stiff, leading to impaired heart function and, in severe cases, heart failure or dangerous arrhythmias. As the heart muscle becomes enlarged, thickened, or rigid, its function deteriorates, reducing its ability to pump blood efficiently. Cardiomyopathy may be inherited (passed down through families) or acquired due to other medical conditions or lifestyle factors. Cardiomyopathy can affect people of any age, gender, or ethnicity. Some types, such as hypertrophic cardiomyopathy, are common genetic conditions, while dilated cardiomyopathy can follow infections or occur after pregnancy. Dilated cardiomyopathy is more prevalent in men and Black individuals, while peripartum cardiomyopathy has a higher risk in women over 30, those with multiple pregnancies, or a history of preeclampsia.
Symptoms include shortness of breath, fatigue or tiredness, swelling in legs, ankles, feet, abdomen, or neck veins, chest pain, dizziness, fainting, and coughing while lying down. Not everyone with cardiomyopathy shows symptoms; some people remain asymptomatic for years, while others develop signs as the disease progresses. Symptoms can worsen over time if untreated.
Cardiomyopathy can impact people of all ages, including children and young adults. Early detection and specialized treatment can significantly improve outcomes.
🦄 3 startups making an impact in this space:
Company | |||
Location | US | Ireland | US |
Modality | Prediction/ Diagnosis | Diagnosis/ Treatment | Digital Therapeutics |
Descriptor | Cardio AI-Powered Cardiology is an advanced multi-agent system designed to revolutionize cardiovascular healthcare. | The Swan-HemoCath™ Critical Care AI Platform is a breakthrough solution that enables diagnosis, treatment, and monitoring of critically ill (ICU) and heart failure (HF) patients. | A biomarker-guided digital therapeutics company that aims to address complex chronic conditions by embedding a sophisticated biomarker platform into simple, easy-to-use devices. |
Core Problem | Analyzing cardiac issues is a manual and cumbersome process and does not leverage multi-modal inputs. | Measuring cardiovascular metrics involves very invasive mechanisms and provides one-off readings. | Cardiac issue diagnosis, monitoring, and treatment require in-hospital stays and rely on complex devices and technology. |
Solution | By integrating and analyzing diverse patient data sources, including EHRs, cardiac imaging, genetic information, and ECGs, their AI agents provide intelligent support for diagnosis, risk assessment, and personalized treatment planning. | This innovative platform combines a minimally invasive HemoCath pulmonary artery catheter with real-time AI-powered monitoring via the Swan AI Cloud™ (B2B AIoT/SaaS). | Advanced sensors and proprietary algorithms noninvasively measure a broad spectrum of hemodynamic biomarkers to assess heart function and fluid status in the patient’s home. |
Product Suite | Real-Time Heart Monitoring that utilizes advanced AI algorithms to provide continuous, real-time monitoring of heart activity. Personalized Risk Assessment that employs machine learning to analyze patient data and provide tailored health recommendations. | HemoCath™ PA Catheter The HemoCath pulmonary artery (PA) catheter enables targeted therapy. The PA catheters transmit real-time cardiovascular hemodynamic data to the Swan AI Cloud™, enabling AI-driven optimal medication dosing. | The Bodyport Cardiac Scale detects signals through a person’s feet and sends data to the clinical care team in seconds. |
Regulatory Status | – | 510K | FDA-cleared device |
Funding Stage | Seed | Seed | Series A |
Team | AI Scientists and Cardiologists | Experienced med tech entrepreneurs | Established healthcare technology leaders. |
Traction | Very early stage | Very early stage | Strong traction with adoption by leading health systems like Stanford and Duke. |
🚀 2 actionable insights to inspire your strategy:
AI/ML | Remote Patient Monitoring |
|---|---|
AI is revolutionizing cardiology by enhancing diagnostics, patient data analysis, and predictive care. It aids in interpreting complex cardiac imaging like echocardiograms and ECGs, automates data interpretation, reduces errors, and detects structural heart diseases earlier than traditional methods. AI-based risk prediction software also helps stratify patients for more effective treatment plans while improving workflow efficiency. | There is a strong trend toward continuous, real-time cardiac monitoring using advanced wearable technologies that patients can use outside clinical settings. These devices track heart rate, rhythm, and other vital signs to detect arrhythmias and manage heart failure remotely. This shift enables patient-led data collection, reduces hospital visits, lowers readmissions, and facilitates personalized, longitudinal care. |
🌟 1 interesting resource:
Take a listen to this episode of the ‘Stuff You Should Know’ podcast to find out if people can die of a broken heart!!
Till next time,